Announcements Trials

Browse Landscape

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Papillomavirus Infections 9 Uterine Cervical Neoplasms 4 Neuroendocrine Tumors 4 Autoimmune Diseases 3 Prostatic Neoplasms 2 Neoplasms 2 Abortion, Spontaneous 2 Recurrence 1 Ovarian Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Neuroblastoma 1 Neoplastic Cells, Circulating 1 Neoplasm Metastasis 1 Myasthenia Gravis 1 Lymphohistiocytosis, Hemophagocytic 1 Lung Neoplasms 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Brain Neoplasms 1

Interventions

Carboplatin 97 Pemetrexed 70 pembrolizumab 68 Cisplatin 59 Paclitaxel 54 Docetaxel 45 Gemcitabine 37 Erlotinib Hydrochloride 24 Nivolumab 23 osimertinib 17 Bevacizumab 17 durvalumab 14 Cetuximab 13 130-nm albumin-bound paclitaxel 13 Gefitinib 11 Drug Therapy 11 Etoposide 10 Ipilimumab 9 Injections 9 Albumin-Bound Paclitaxel 9 Vinorelbine 8 Radiotherapy 8 motexafin gadolinium 7 capmatinib 7 epacadostat 6 atezolizumab 6 Taxes 6 Cyclophosphamide 6 vandetanib 5 entinostat 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Lung Neoplasms × Data Collection × Clear all

NCT02300831 2017-07-14

LUMINIST

AstraZeneca

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡